Amlodipine Diabetic Hypertension Efficacy Response Trial (ADHERE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00159692|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : February 10, 2009
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Amlodipine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||739 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating The Safety and Efficacy Of The Addition Of Amlodipine To Quinapril Or Losartan In The Treatment Of Diabetic Hypertensive Subjects|
|Study Start Date :||March 2003|
|Actual Study Completion Date :||August 2005|
- The percentage of subjects that reach the JNC diabetic hypertensive BP goal of <130/80 will be assessed at Week 0 (Visit 2-Randomization), Week 5 (Visit 3), Week 9 (Visit 4), Week 15 (Visit 5) and Week 20 (Visit 6 - Final Evaluation).
- Percentage of subjects at SBP goal of <130 mmHg and DBP goal of <80mmHg; change from baseline blood pressures (SBP and DBP); percentage of subjects with SBP >160mmHg and/or DBP >100mmHg at Visits 2, 3, 4, 5, 6.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159692
|Study Director:||Pfizer CT.gov Call Center||Pfizer|